CRITICAL PATH INSTITUTE

Shaping the Future of AATD: Patient Perspectives to Drive the Next Decade of Innovation in Alpha-1 Antitrypsin Deficiency

On September 8, C-Path and the Alpha-1 Foundation co-hosted a virtual workshop, Shaping the Future of AATD: Patient Perspectives to Drive the Next Decade of Innovation in Alpha-1 Antitrypsin Deficiency. Patients play a vital role in advancing research—by sharing experiences, contributing data, and advocating for earlier and better detection, therapies, and cures. That's why participation from the AATD community was essential; this workshop was tailored for anyone living with the deficiency, and/or any supporters of people living with AATD, to ensure the patient voice is heard. Together, we accelerate progress for all of those impacted by AATD.

The Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) Consortium's mission is to forge actionable, regulatory-approved drug development solutions for patients living with AATD, by working with key stakeholders in a public-private partnership dedicated to open collaboration.

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.